Phase II trial of androgen deprivation therapy (ADT) and pembrolizumab for advanced stage androgenreceptor-positive salivary gland carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111

Project: Research project

Project Details

Description

Phase II trial of androgen deprivation therapy (ADT) and pembrolizumab for advanced stage androgen receptor-positive salivary gland carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111
StatusActive
Effective start/end date9/17/18 → 9/30/25

Funding

  • BIG TEN CANCER RESEARCH CONSORTIUM
  • MERCK, SHARP & DOHME LLC

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
View full fingerprint